Clinical Trial Update: A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Memorial Sloan Kettering Cancer Center is evaluating a combination of Ivosidenib, Azacitidine, and Venetoclax followed by Ivosidenib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tibsovo (ivosidenib)
• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING